Immatics N.V.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Immatics N.V. now
Current reporting with the operating signal separated from the noise.
Guggenheim Initiates Coverage of Immatics N.V. (IMTX) with Buy Recommendation
The story matters when it changes Immatics N.V.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Immatics N.V. Reports Promising Long-Term Efficacy and Safety Data from Phase 1b Trial of IMA203 PRAME Cell Therapy in Metastatic Melanoma
The story matters when it changes Immatics N.V.’s customers, execution, competitive position or capital requirements.
Watch next: regulator filings, verified operating scope and liability disclosures.Latest IMTX filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Immatics N.V., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →